Form 8-K - Current report:
SEC Accession No. 0001140361-25-002103
Filing Date
2025-01-28
Accepted
2025-01-27 21:28:58
Documents
13
Period of Report
2025-01-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K ef20042399_8k.htm   iXBRL 8-K 28816
  Complete submission text file 0001140361-25-002103.txt   164059

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rckt-20250125.xsd EX-101.SCH 3994
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rckt-20250125_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rckt-20250125_pre.xml EX-101.PRE 16052
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20042399_8k_htm.xml XML 4057
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36829 | Film No.: 25560699
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)